Investigational Drug Information for Bitopertin
What is the drug development status for Bitopertin?
Bitopertin is an investigational drug.
There have been 15 clinical trials for Bitopertin.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 4th 2025.
The most common disease conditions in clinical trials are Schizophrenia, Protoporphyria, Erythropoietic, and Protoporphyria, Erythropoietic, X-Linked Dominant. The leading clinical trial sponsors are Hoffmann-La Roche, Disc Medicine, Inc, and Karolinska Institutet.
There are one hundred and five US patents protecting this investigational drug and five hundred and sixty international patents.
Summary for Bitopertin
| US Patents | 105 |
| International Patents | 560 |
| US Patent Applications | 233 |
| WIPO Patent Applications | 67 |
| Japanese Patent Applications | 12 |
| Clinical Trial Progress | Phase 3 (2025-04-04) |
| Vendors | 48 |
Recent Clinical Trials for Bitopertin
| Title | Sponsor | Phase |
|---|---|---|
| Effect of Bitopertin on the Liver and on Levels of Protoporphyrin IX in Bile, Blood, Liver, and Stool in Patients With Erythropoietic Protoporphyria/X-linked Protoporphyria and Increased Liver Stiffness and/or Liver Enzymes at Baseline | Wake Forest University Health Sciences | PHASE1 |
| Study of Bitopertin in Participants With EPP or XLP (APOLLO) | Disc Medicine, Inc | PHASE3 |
| Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP | Disc Medicine, Inc | Phase 2/Phase 3 |
Clinical Trial Summary for Bitopertin
Top disease conditions for Bitopertin
Top clinical trial sponsors for Bitopertin
US Patents for Bitopertin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Bitopertin | ⤷ Start Trial | 2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,- 3-thiazol-4-yl amides | Pfizer Inc. (New York, NY) | ⤷ Start Trial |
| Bitopertin | ⤷ Start Trial | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | Pfizer Inc. (New York, NY) | ⤷ Start Trial |
| Bitopertin | ⤷ Start Trial | Methods of treating acanthamoeba infection using apocynin | UNIVERSITY OF SOUTH FLORIDA (Tampa, FL) | ⤷ Start Trial |
| Bitopertin | ⤷ Start Trial | Imidazopyridazine compounds | Pfizer Inc. (New York, NY) | ⤷ Start Trial |
| Bitopertin | ⤷ Start Trial | SHMT inhibitors | Princeton University | ⤷ Start Trial |
| Bitopertin | ⤷ Start Trial | N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiaz- in-8a(8H)-YL)-1,3-thiazol-4-YL] amides | Pfizer Inc. (New York, NY) | ⤷ Start Trial |
| Bitopertin | ⤷ Start Trial | 5-HT3 receptor antagonists | Takeda Pharmaceutical Co Ltd , Envoy Therapeutics Inc | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Bitopertin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Bitopertin | Argentina | AR099997 | 2034-04-10 | ⤷ Start Trial |
| Bitopertin | Australia | AU2015245260 | 2034-04-10 | ⤷ Start Trial |
| Bitopertin | Canada | CA2944971 | 2034-04-10 | ⤷ Start Trial |
| Bitopertin | Chile | CL2016002510 | 2034-04-10 | ⤷ Start Trial |
| Bitopertin | China | CN106459088 | 2034-04-10 | ⤷ Start Trial |
| Bitopertin | Costa Rica | CR20160455 | 2034-04-10 | ⤷ Start Trial |
| Bitopertin | Cuba | CU20160151 | 2034-04-10 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
